Reducing mortality from 2019-nCoV: host-directed therapies should be an option

The Lancet

Volumn 395, Issue 10224, 2020, Pages e35-e36

  Zumla, Alimuddin ^a,b   Hui, David S ^c   Azhar, Esam I ^d   Memish, Ziad A ^e,f   Maeurer, Markus ^g,h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e Ministry of Health ^*  (Saudi Arabia)

^f ALFAISAL UNIVERSITY   (Saudi Arabia)

^g CHAMPALIMAUD CENTRE FOR THE UNKNOWN   (Portugal)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ATORVASTATIN; CYCLOSPORINE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; INTERFERON BETA SERINE; INTERLEUKIN 17; LOPINAVIR PLUS RITONAVIR; METFORMIN; MONOCLONAL ANTIBODY; REMDESIVIR; RIBAVIRIN; SARTAN DERIVATIVE; TOCILIZUMAB; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2;

CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; CRITICALLY ILL PATIENT; CYTOKINE STORM; DISEASE ASSOCIATION; DISEASE MANAGEMENT; DRUG REPOSITIONING; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; INTENSIVE CARE; LETTER; LUNG FIBROSIS; MESENCHYMAL STROMA CELL; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY OF LIFE; SARS-RELATED CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; T LYMPHOCYTE; TH2 CELL; TISSUE REGENERATION; WORLD HEALTH ORGANIZATION; BETACORONAVIRUS; DRUG DEVELOPMENT; GLOBAL HEALTH;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; DRUG DISCOVERY; GLOBAL HEALTH; HUMANS;

EID: 85079618761     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(20)30305-6     Document Type: Letter

References (15)

1. WHO. Novel coronavirus (2019-nCoV) situation report - 14. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200203-sitrep-14-ncov.pdf?sfvrsn=f7347413_2, Feb 3, 2020. (Accessed 3 February 2020)
2. Hui, DSC, Zumla, A, Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am 33 (2019), 869–889.
3. Azhar, EI, Hui, DSC, Memish, ZA, Drosten, C, Zumla, A, The Middle East respiratory syndrome (MERS). Infect Dis Clin North Am 33 (2019), 891–905.
4. Huang, C, Wang, Y, Li, X, Clinical features of patients infected with 2019 coronavirus in Wuhan, China. Lancet, 2020 published online Jan 24 https://doi.org/10.1016/S0140-6736(20)30183-5.
5. Li, G, Fan, Y, Lai, Y, et al. Coronavirus infections and immune responses. J Med Virol, 2020 published online Jan 25. DOI:10.1002/jmv.25685.
6. Channappanavar, R, Perlman, S, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39 (2017), 529–539.
7. Batawi, S, Tarazan, N, Al-Raddadi, R, et al. Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health Qual Life Outcomes, 17, 2019, 101.
8. Ngai, JC, Ko, FW, Ng, SS, To, KW, Tong, M, Hui, DS, The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology 15 (2010), 543–550.
9. Zumla, A, Chan, JF, Azhar, EI, Hui, DS, Yuen, KY, Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 15 (2016), 327–347.
10. Beigel, JH, Nam, HH, Adams, PL, et al. Advances in respiratory virus therapeutics—a meeting report from the 6th ISIRV antiviral group conference. Antiviral Res 167 (2019), 45–67.
11. Zumla, A, Azhar, EI, Arabi, Y, et al. Host-directed therapies for improving poor treatment outcomes associated with the Middle East respiratory syndrome coronavirus infections. Int J Infect Dis 40 (2015), 71–74.
12. Barnard, DL, Wong, MH, Bailey, K, et al. Effect of oral gavage treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus infections in mice. Antivir Chem Chemother 18 (2007), 125–132.
13. Horie, S, Gonzalez, HE, Laffey, JG, Masterson, CH, Cell therapy in acute respiratory distress syndrome. J Thorac Dis 10 (2018), 5607–5620.
14. Davies, R, O'Dea, K, Gordon, A, Immune therapy in sepsis: are we ready to try again?. J Intensive Care Soc 19 (2018), 326–344.
15. Lerias, JR, Paraschoudi, G, Silva, I, et al. Clinically relevant immune responses against cytomegalovirus: implications for precision medicine. Int J Mol Sci, 20, 2019, 1986.